Compare FRT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | PCVX |
|---|---|---|
| Founded | 1962 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 7.0B |
| IPO Year | 1994 | 2020 |
| Metric | FRT | PCVX |
|---|---|---|
| Price | $112.30 | $60.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $112.08 | $88.25 |
| AVG Volume (30 Days) | 564.4K | ★ 1.0M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ 36.84 | N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | ★ $1,278,975,000.00 | N/A |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $62.88 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $90.03 | $30.81 |
| 52 Week High | $128.21 | $65.00 |
| Indicator | FRT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 30.16 | 55.15 |
| Support Level | $112.67 | $58.51 |
| Resistance Level | $119.41 | $63.39 |
| Average True Range (ATR) | 1.50 | 1.98 |
| MACD | -0.15 | -0.28 |
| Stochastic Oscillator | 7.01 | 54.29 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 103 properties, which includes 28.8 million square feet of retail space and 2,500 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.